|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Department of Pharmacokinetics |
MIURA Masatomo
|
|
|
Graduating School 【 display / non-display 】
-
-1992.03
Tohoku Pharmaceutical University Faculty of Pharmaceutical Science Graduated
Graduate School 【 display / non-display 】
-
-1994.03
Tohoku Pharmaceutical University Graduate School, Division of Pharmaceutical Sciences Master's Course Completed
Campus Career 【 display / non-display 】
-
2021.12-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Department of Pharmacokinetics Professor
-
2013.04-2021.11
Akita University Hospital Department of Pharmacy Professor
Research Achievements 【 display / non-display 】
-
Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
Masatomo,Miura
Ther Drug Monit 29 ( 299 ) 304 2007.01
Research paper (journal) Single author
-
Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
Masatomo,Miura
Eur J Clin Pharmacol 63 ( 279 ) 288 2007.01 [Refereed]
Research paper (journal) Single author
-
Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography
Masatomo,Miura
J Pharm Biomed Anal 43 ( 741 ) 745 2007.01
Research paper (journal) Single author
-
Pharmacokinetics of fexofenadine enantiomers in healthy subjects
Masatomo,Miura
Chirality 19 ( 223 ) 227 2007.01
Research paper (journal) Single author
-
Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo
YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan ) 143 ( 4 ) 377 - 383 2023
-
Fukushi Yayoi, Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo
YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan ) 143 ( 11 ) 963 - 969 2023
-
Tsuji Daiki, Saito Yoshiro, Mushiroda Taisei, Miura Masatomo, Hira Daiki, Terada Tomohiro
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ( Japanese Society of Pharmaceutical Health Care and Sciences ) 46 ( 2 ) 66 - 76 2020
<p>Given that the cancer gene panel test was approved in June 2019, precision medicine based on the information about somatic mutation is expected to be widely available. Similarly, pharmacogenomics (PGx) associated with germline genes, such as drug-metabolizing enzymes, could also be effective tools. However, its clinical implementation has been delayed.</p><p>To address this issue, we conducted a survey regarding pharmacists' involvement in "cancer genomic medicine (CGM)" and actual use of PGx and therapeutic drug monitoring (TDM). The response rate of the survey was 96.8% (121/125).</p><p>According to this survey, genetic polymorphism analysis for irinotecan (UGT1A1), which is approved for genetic testing, was most commonly used. Among the tests not covered by insurance, tacrolimus (CYP3A5) and voriconazole (CYP2C19) were commonly used. Only a few facilities conducted PGx tests. Unlike PGx, many drugs are covered by insurance for TDM, which was commonly used. Vancomycin was most commonly used, followed by teicoplanin and cyclosporine. Regarding CGM, it was found that the pharmacists were most commonly involved in dose adjustment support, followed by support for selection of anti-cancer agents. Pharmacists' participation in the expert panel was 21.3%.</p><p>This survey revealed that PGx testing is less common compared with TDM. PGx of drug-metabolizing enzymes could potentially influence adverse reactions and efficacy. It might be possible to provide individualized pharmacotherapy if PGx testing could be performed at the same time as gene panel tests. Insurance-covered PGx testing may increase in the future if more high-quality clinical trials are conducted and its usefulness is validated.</p>
-
Personalized medicine for oral molecular-targeted anticancer drugs
Miura Masatomo
Folia Pharmacologica Japonica ( The Japanese Pharmacological Society ) 153 ( 2 ) 73 - 78 2019
<p>Therapeutic drug monitoring (TDM) is carried out by evaluating drug plasma (or serum) concentrations in response to individual optimal treatments by dose adjustment to improve efficacy or avoid side effects. Many molecular-targeted anticancer drugs show exposure-efficacy and exposure-toxicity relationships. Therefore, plasma concentrations of anticancer drugs can be used as biomarkers. However, to carry out TDM, therapeutic target ranges indicating exposure-response (efficacy/toxicity) relationships must be determined. In Japan, treatment fees for managing the TDM of imatinib and sunitinib have been assessed since 2012 and 2018, respectively. In therapy for imatinib or sunitinib using TDM, reduced toxicity, discontinuation rates, and costs for treatments as well as improved clinical efficacy have been noted. To establish the use of TDM in clinical practice, it is necessary to determine target plasma concentrations (minimum effective concentration or minimum toxic concentration) of many molecular-targeted anticancer drugs by retrospective and prospective clinical trials. In these clinical trials, analytical methods with high precision are needed. By carrying out TDM, we may determine the optimal anticancer therapy for patients as precision medicine after the start of therapy.</p>
-
MIURA Masatomo, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 60 ( 9 ) 1140 - 1147 2019
<p>Imatinib, nilotinib, dasatinib, bosutinib, and ponatinib are tyrosine kinase inhibitors used to treat chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) and target concentration intervention (TCI) are novel strategies that use concentration-controlled dosing (CCD) to attain a faster and more profound clinical response in patients with CML. The target plasma trough concentration (<i>C</i><sub>0</sub>) of imatinib is 1,000 ng/m<i>l</i> to obtain a higher major molecular response (MMR) rate. Target nilotinib and bosutinib <i>C</i><sub>0</sub> of 900 and 62 ng/m<i>l</i>, respectively, are recommended to attain a better response, whereas a target ponatinib <i>C</i><sub>0</sub> of 21.3 ng/m<i>l</i> has been proposed to obtain a better response and decrease the risk of adverse events, such as vascular toxicity. Approaches for these four TKIs involve the use of TCI with specific target concentrations rather than TDM with a therapeutic range. Conversely, for dasatinib, a lower <i>C</i><sub>0</sub> of <4.33 ng/m<i>l</i> is the maximum toxic concentration recommended to avoid pleural effusion. Therefore, precision dosing using CCD of TKIs for CML could maximize the clinical benefit and minimize toxicity.</p>
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2020.04 - 2022.03